NOT KNOWN DETAILS ABOUT GLOBAL

the information through the PURPOSE 1 and reason 2 trials will support future regulatory filings to ensure that 2 times-yearly lenacapavir for PrEP, if accredited, can be approved for various populations and communities all over the world that are most looking for extra HIV avoidance options. This can be the 2nd pivotal section three demo to demon